4.3 Review

Ciclosporin A Cationic Emulsion 0.1% for the Management of Dry Eye Disease: Facts That Matter for Eye-Care Providers

Journal

OCULAR IMMUNOLOGY AND INFLAMMATION
Volume 31, Issue 8, Pages 1707-1715

Publisher

TAYLOR & FRANCIS INC
DOI: 10.1080/09273948.2022.2088566

Keywords

Ciclosporin; corneal healing; dry eye disease; expert review; keratitis; literature review

Categories

Ask authors/readers for more resources

Dry eye disease is a chronic inflammatory disease of the ocular surface that requires long-term therapy. Treatment with ciclosporin A 0.1% cationic emulsion can improve clinical signs and symptoms as early as 4 weeks after treatment initiation.
Dry eye disease (DED) is a chronic inflammatory disease of the ocular surface requiring long-term therapy. Severe forms of DED generally do not respond to tear substitutes alone or combined, and often require treatment with topical anti-inflammatory agents to break the vicious circle of inflammation. This review summarises data from randomised controlled trials and real-world evidence on the efficacy and safety of ciclosporin A 0.1% cationic emulsion (Ikervis (R)) for the management of DED. Improvements in clinical signs and symptoms were reported from as early as 4 weeks after treatment initiation, although it can take a few months to reach the full benefits. Treatment periods of up to 12 months provide sustained benefit to patients. In the most responsive patients, treatment discontinuation is possible with no further substantial relapse over 12 months in over 65% of patients. Transient local ocular effects are the most commonly reported adverse events.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available